Overview

Special Combination of BBI608 and Pembrolizumab

Status:
Terminated
Trial end date:
2021-08-23
Target enrollment:
Participant gender:
Summary
the efficacy and safety of BBI608 in combination with pembrolizumab
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Takayuki Yoshino
Collaborator:
Sumitomo Dainippon Pharma Co., Ltd.
Treatments:
Pembrolizumab